Is NAD+ approved or legal?

NAD+ is not an FDA-approved drug for anti-aging or longevity. Injectable NAD+ is typically a compounded product, and oral precursors (NR, NMN) are sold as supplements with evolving regulatory status. It is framed here for research and educational use only, not as an approved treatment.

What is the half-life of NAD+ and how long does a dose last?

Circulating NAD+ has no clean, well-defined half-life. IV-infused NAD+ is rapidly sequestered and broken down into metabolites within hours, so intact NAD+ does not persist long in blood; effects depend on salvage of those metabolites rather than a sustained plasma level.

Does NAD+ actually have proven anti-aging benefits in humans?

Not robustly. Oral precursors reliably raise blood NAD+ and are well tolerated, but human trials have shown only small, inconsistent functional benefits so far. Strong anti-aging claims are not supported by current controlled evidence.

What side effects are reported with NAD+ injections or IV?

Commonly nausea, flushing or warmth, sweating, abdominal cramping, headache, chest tightness and lightheadedness, usually transient and worse with faster delivery. Slower, smaller dosing and hydration are reported to reduce these. Long-term safety of chronic injection is not established.

Is oral NMN/NR or injected NAD+ better?

Oral NR and NMN have the most controlled human data for raising NAD+ and good tolerability. Injected/IV NAD+ is largely metabolized before entering cells, so its advantage over precursors is uncertain. Neither has proven superior functional outcomes in rigorous trials.

Longevity

NAD+

Also known as: Nicotinamide adenine dinucleotide, NAD, NAD plus

NAD+ is a core metabolic coenzyme; boosting it is widely studied for aging, but human benefit data remain limited and mixed.

Last updated July 11, 2026

Reconstitute this peptide Buy NAD+

Overview

Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme present in every living cell. It is central to energy metabolism (glycolysis, the TCA cycle, oxidative phosphorylation) where it shuttles electrons as NAD+/NADH, and it is also consumed as a substrate by enzymes such as sirtuins, PARPs (DNA repair), and CD38. Tissue NAD+ is reported to decline with age, which has made restoring NAD+ a prominent target in longevity research. Most human evidence concerns oral NAD+ precursors rather than NAD+ itself, chiefly nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). These precursors reliably raise blood NAD+ in trials and are generally well tolerated, but translation into clear functional benefits (strength, cognition, metabolic markers) has so far been modest and inconsistent. NAD+ administered directly is used clinically and in wellness clinics mainly as slow intravenous (IV) infusion, and increasingly as compounded subcutaneous/intramuscular injection. Pharmacokinetic work shows IV NAD+ is rapidly taken up and broken down into metabolites rather than circulating intact, which complicates interpretation of how much usable NAD+ a dose actually delivers. This profile is for research and educational reference only. NAD+ and its precursors are not approved drugs for anti-aging, and injectable NAD+ products are typically compounded rather than FDA-approved.

How it works

NAD+ functions in two broad ways. As a redox cofactor it cycles between NAD+ and NADH to carry electrons through central energy pathways, supporting ATP production. As a signaling substrate it is consumed by NAD+-dependent enzymes: sirtuins (which influence mitochondrial biogenesis, inflammation, and stress responses), PARPs (DNA-damage repair), and CD38/CD157 (a major NAD+-consuming enzyme that rises with age and inflammation). Because these consuming enzymes degrade NAD+, intracellular levels depend on continuous resynthesis via salvage pathways using precursors such as nicotinamide, NR, and NMN. The leading rationale for supplementation is that raising substrate availability restores age-associated NAD+ decline and thereby supports sirtuin/PARP activity and mitochondrial function. Direct IV/injected NAD+ appears to be largely metabolized extracellularly (e.g., to nicotinamide, ADP-ribose, NMN) and salvaged, rather than entering cells intact.

Researched effects

Clinical Oral NAD+ precursors (NR, NMN) reliably increase blood/tissue NAD+ levels in healthy adults
Clinical NMN 250 mg/day for 12 weeks produced small (nominally significant) gains in gait speed and grip strength in older men, without changes in muscle mass
Clinical NAD+ precursor supplementation is generally well tolerated over weeks to months in healthy and older adults
Preclinical Restoring NAD+ mitigates oxidative stress, DNA damage, neurodegeneration and metabolic dysfunction in animal and cell models
Preclinical NAD+ supports sirtuin and PARP activity and mitochondrial function in preclinical aging models
Anecdotal Users report improved energy, mood, mental clarity and reduced fatigue after IV or subcutaneous NAD+
Anecdotal Used anecdotally as an adjunct for recovery and craving reduction in substance-use contexts

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No established clinical dosing for NAD+ itself as an approved anti-aging therapy. Research/clinical examples: IV NAD+ has been studied at 750 mg infused over ~6 hours in healthy men (well tolerated). For oral precursors, trials commonly use nicotinamide riboside ~250-1000 mg/day and nicotinamide mononucleotide ~250-500 mg/day for several weeks to months, both shown to raise blood NAD+. Injectable NR/NAD+ products are early-stage (e.g., open-label safety studies of 50-100 mg subcutaneous/intramuscular). Direct IV NAD+ is largely metabolized rather than entering cells intact, so effective delivered dose is uncertain.

Community-reported dosing (anecdotal)

Anecdotal and research-reference only; NOT medical advice or instruction. Community and wellness-clinic guides (peptide forums, IV/compounding-pharmacy protocols, and r/Peptides discussion) commonly describe subcutaneous NAD+ around 50-150 mg per injection (most often ~100 mg), starting low (e.g., 0.1 mL to assess tolerance) and titrating up over 1-2 weeks, given 2-3 times weekly. A reported "loading" approach is ~100-200 mg most days for 7-10 days, then maintenance 2-3x/week or a periodic IV session (250-500 mg over 2+ hours, every 4-8 weeks). Slow, smaller doses are reported to reduce flushing, nausea and chest pressure. These figures vary widely between sources, are not validated by controlled trials, and should not be taken as a recommendation.

Half-life: Short and not well defined for circulating NAD+. IV-infused NAD+ is rapidly sequestered/metabolized (little change in plasma for ~2 h during infusion, then a transient rise that declines within hours of stopping); intact NAD+ does not persist long in blood. Effective duration depends on conversion to and salvage of metabolites rather than a clean plasma half-life.
Routes: subcutaneous, intramuscular, intravenous, oral

Safety & side effects

NAD+ and its precursors are generally well tolerated in trials, but injectable/IV NAD+ commonly causes infusion-related effects: nausea, flushing/warmth, sweating, abdominal cramping, headache, chest tightness, and lightheadedness, especially with faster delivery. These are usually transient (minutes to a couple of hours) and reduced by slower, smaller dosing and hydration. Long-term safety of high-dose or chronic NAD+ injection is not established. Theoretical concerns about NAD+ availability and cell proliferation mean caution is warranted in those with active or prior cancer; data are insufficient. Injectable NAD+ is typically a compounded product with variable quality. Pregnancy, breastfeeding, and significant medical conditions are not adequately studied. Research use only; consult a qualified clinician before any human use.

Research summary

The strongest human evidence for the NAD+ pathway comes from oral precursors. Multiple randomized, placebo-controlled trials show nicotinamide riboside and nicotinamide mononucleotide are well tolerated and reliably raise blood NAD+ in middle-aged and older adults. However, downstream functional benefits have been limited and inconsistent: for example, a 12-week NMN 250 mg/day trial in older men found only small, nominally significant improvements in gait speed and one grip-strength measure, with no change in muscle mass or several other endpoints. Recent reviews conclude that while preclinical data are compelling, human clinical efficacy for healthy-aging outcomes remains modest and unproven. For NAD+ given directly, pharmacokinetic work (e.g., a 750 mg, 6-hour IV infusion study) shows infused NAD+ is rapidly removed from circulation and appears as metabolites such as nicotinamide, ADP-ribose, methyl-nicotinamide and NMN, suggesting much of the dose is degraded extracellularly and salvaged rather than entering cells intact. This raises real questions about how efficiently IV/injected NAD+ raises functional intracellular NAD+ compared with oral precursors. Overall, NAD+ is a biologically central and actively studied longevity target with a reasonable safety record at studied doses, but claims of robust anti-aging, cognitive, or recovery benefits in humans outrun the current controlled evidence. Community injection protocols are anecdotal, vary widely, and should be treated as research reference rather than guidance. Larger, longer, outcome-focused human trials are needed.

FAQ

Is NAD+ approved or legal?: NAD+ is not an FDA-approved drug for anti-aging or longevity. Injectable NAD+ is typically a compounded product, and oral precursors (NR, NMN) are sold as supplements with evolving regulatory status. It is framed here for research and educational use only, not as an approved treatment.
What is the half-life of NAD+ and how long does a dose last?: Circulating NAD+ has no clean, well-defined half-life. IV-infused NAD+ is rapidly sequestered and broken down into metabolites within hours, so intact NAD+ does not persist long in blood; effects depend on salvage of those metabolites rather than a sustained plasma level.
Does NAD+ actually have proven anti-aging benefits in humans?: Not robustly. Oral precursors reliably raise blood NAD+ and are well tolerated, but human trials have shown only small, inconsistent functional benefits so far. Strong anti-aging claims are not supported by current controlled evidence.
What side effects are reported with NAD+ injections or IV?: Commonly nausea, flushing or warmth, sweating, abdominal cramping, headache, chest tightness and lightheadedness, usually transient and worse with faster delivery. Slower, smaller dosing and hydration are reported to reduce these. Long-term safety of chronic injection is not established.
Is oral NMN/NR or injected NAD+ better?: Oral NR and NMN have the most controlled human data for raising NAD+ and good tolerability. Injected/IV NAD+ is largely metabolized before entering cells, so its advantage over precursors is uncertain. Neither has proven superior functional outcomes in rigorous trials.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.